OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment

OS Therapies Inc. (NYSE: OSTX) reported a 72.7% three-year survival rate for patients treated with its OST-HER2 therapy in a Phase 2b trial for pulmonary metastatic osteosarcoma, compared to 45.8% in a historical control group. The World Health Organization has accepted the brand name Herlystic for the therapy, and the company plans to finalize submissions for early market access in the U.S., U.K., Europe, and Australia by Q4 2026. OST-HER2 has received multiple regulatory designations from the FDA, and the company intends to sell a Priority Review Voucher if granted, following a similar voucher's sale for $220 million in August 2026. As of the latest update, OSTX shares are trading at $1.56, down 2.19%.